Dapagliflozin for treating heart failure with reduced ejection fraction – the NICE TAG – Talking Head Video

AstraZeneca have provided financial support for this blended learning series and have had no involvement in the content or speaker selection

Dr Jim Moore recorded this Talking Head video on behalf of the PCCS. He describes the NICE TAG for dapagliflozin for the symptomatic treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). It provides members of the PCCS with advice on how they can identify patients suitable for treatment and how the guidance can be implemented in clinical practice.

President of the Primary Care Cardiovascular Society, GP, GPSI Cardiology, Gloucestershire

Dr Moore studied medicine in Edinburgh before moving to Gloucestershire to work as a GP principal. He has an interest in cardiology and cardiovascular disease, particularly those aspects that are relevant to primary care and contributes regularly to related educational events across the UK. He is President of the primary care cardiovascular society.

Dr Moore was involved in the development of the Primary Care based Gloucestershire Heart Failure service where he continues to work as a GPwSI.

He continues to represent Primary Care in the cardiovascular arena at both a local and national level. He has provided cardiovascular clinical support to local commissioning organisations for over ten years and remains actively involved in commissioning local cardiology services chairing the Circulatory Clinical Programme Group for Gloucestershire Clinical Commissioning Group (CCG). He was Clinical Lead for the community based West of England AHSN Stroke Prevention in AF project: Don’t wait to anticoagulate.

Dr Moore previously served on the board of the British Society for Heart Failure and was a member of the NICE Chronic Heart Failure Guideline committee (2018). He currently sits on the National Heart Failure Audit Steering group.